Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Formoterol (6mcg) + Tiotropium (9mcg)
Therapeutic Category
General and OTC medicines, Pulmonary, Respiratory, Asthma
Dosage Form
Inhaler
Packaging Type
Metered Dose with Carton and Leaflet
Packaging
120
Price
₹1/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Tropiturn F 6/9 Inhaler is a combination of Formoterol and Tiotropium, two bronchodilators that work together to open up the airways and make breathing easier. Formoterol, a long-acting beta-agonist (LABA), helps to relax the muscles in the airways, allowing for improved airflow. Tiotropium, an anticholinergic agent, works by inhibiting the action of acetylcholine on airway smooth muscles, leading to prolonged bronchodilation. This combination is primarily used in the management of chronic obstructive pulmonary disease (COPD) and asthma to reduce symptoms such as wheezing, shortness of breath, and chest tightness.
Common side effects may include dry mouth, throat irritation, cough, and headache. Less common side effects include dizziness, nausea, and palpitations.
Used for the long-term management of chronic obstructive pulmonary disease (COPD) and asthma.
Do not exceed the recommended dosage. Not for the treatment of acute asthma attacks. Consult a healthcare professional before use if you have heart or lung conditions.
Store in a cool, dry place away from direct sunlight. Keep out of reach of children.
Composition : Formoterol (12mcg) + Tiotropium (18mcg)
Composition : Formoterol (6mcg) + Fluticasone Propionate (250mcg)
Composition : Formoterol (6mcg) + Budesonide (400mcg) Inhaler
Composition : Formoterol (6mcg) + Budesonide (200mcg) Inhaler
Composition : Salmeterol (25mcg) + Fluticasone Propionate (500mcg)
Composition : Salmeterol (25mcg) + Fluticasone Propionate (250mcg)
Composition : Levosalbutamol 100mcg + Ipratropium 40mcg
Composition : Salmeterol (50mcg) + Fluticasone Propionate (250mcg)
Composition : Fluticasone Propionate 250mcg + Formoterol Fumarate 6mcg Life Cap
Composition : Salmeterol (50mcg) + Fluticasone Propionate (500 mcg)
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
This is a dual bronchodilator inhalation therapy used for the management of moderate to severe COPD (Chronic Obstructive Pulmonary Disease) and in some cases chronic asthma maintenance therapy. Formoterol is a long-acting beta-2 agonist (LABA) that helps relax airway muscles quickly and improve breathing Tiotropium is a long-acting muscarinic antagonist (LAMA) that helps keep airways open for long duration Together, they provide dual bronchodilation for better lung function and symptom control, making it a strong respiratory and pulmonology segment product.
Medical distributors and wholesalers can benefit from steady long-term demand from pulmonologists, chest physicians, and hospitals. COPD is a chronic progressive disease requiring daily maintenance therapy, ensuring continuous refill prescriptions, strong patient dependency, and stable monthly sales.
Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities in respiratory, pulmonary care, and inhalation therapy segments with monopoly rights, quality manufacturing standards, and reliable supply support for distributors and medical agencies.
Wholesalers and medical agencies benefit from high chronic disease burden, long-term prescription continuity, and strong specialist-driven demand, making it a stable, high-value, and repeat-order pharmaceutical category when partnered with Cafoli Lifecare.
Medical distributors, stockists, and pharma professionals interested in respiratory and inhalation therapy products can contact Cafoli Lifecare to discuss product availability, pricing structure, and PCD pharma franchise opportunities in the pulmonology and chronic respiratory segment.